+ All Categories
Home > Documents > Presenter Disclosure Information

Presenter Disclosure Information

Date post: 07-Jan-2016
Category:
Upload: kyrene
View: 22 times
Download: 0 times
Share this document with a friend
Description:
Readmission for Stroke and Quality of Care among Patients Hospitalized with Transient Ischemic Attack (TIA): Findings from Get With The Guidelines (GWTG)-Stroke. - PowerPoint PPT Presentation
24
Readmission for Stroke and Quality of Care among Patients Hospitalized with Transient Ischemic Attack (TIA): Findings from Get With The Guidelines (GWTG)-Stroke Emily C. O’Brien 1 , Xin Zhao 1 , Gregg C. Fonarow 2 , Eric E. Smith 3 , Lee H. Schwamm 4 , Deepak L. Bhatt 5 , Ying Xian 1 , Jeffrey L. Saver 2 , Mathew J. Reeves 6 , Eric D. Peterson 1 , Adrian F. Hernandez 1 1 Duke Clinical Research Institute, Durham, NC; 2 Ronald-Reagan UCLA Medical Center, Los Angeles, CA; 3 Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada; 4 Massachusetts General Hospital, Harvard Medical School, Boston, MA; 5 VA Boston Medical Center, Harvard Medical School, Boston, MA; 6 Michigan State University, East Lansing, MI
Transcript
Page 1: Presenter Disclosure Information

Readmission for Stroke and Quality of Care among Patients Hospitalized with Transient

Ischemic Attack (TIA): Findings from Get With The Guidelines (GWTG)-Stroke

Emily C. O’Brien1, Xin Zhao1, Gregg C. Fonarow2, Eric E. Smith3, Lee H. Schwamm4, Deepak L. Bhatt5, Ying Xian1, Jeffrey L. Saver2, Mathew J.

Reeves6, Eric D. Peterson1, Adrian F. Hernandez1

1Duke Clinical Research Institute, Durham, NC; 2Ronald-Reagan UCLA Medical Center, Los Angeles, CA; 3Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada;

4Massachusetts General Hospital, Harvard Medical School, Boston, MA; 5VA Boston Medical Center, Harvard Medical School, Boston, MA; 6Michigan State University, East Lansing, MI

Page 2: Presenter Disclosure Information

Presenter Disclosure Information

DISCLOSURE INFORMATION:

Name: Emily O’Brien, PhD Title: Readmission for Stroke and Quality of Care among Patients Hospitalized with Transient Ischemic Attack (TIA): Findings from Get With The Guidelines (GWTG)-Stroke

Disclosures:

The American Heart Association and the American Stroke Association fund Get With The Guidelines-Stroke. The program has been supported in part by

unrestricted educational grants to the American Heart Association by Pfizer, Inc., New York, NY, and the Merck-Schering Plough Partnership (North Wales, PA).

Page 3: Presenter Disclosure Information

Background• Transient Ischemic Attack (TIA) is associated with a

markedly elevated risk for ischemic stroke

• Comprehensive risk prediction tools encompassing readily available variables may enhance identification of patients at risk for recurrent stroke

• Evidence-based management of TIA may reduce the risk of recurrent stroke

• The benefit of optimal clinical management in the context of underlying risk has not been fully explored

Page 4: Presenter Disclosure Information

Objectives

1. Estimate risk of one-year admission for ischemic stroke after TIA hospitalization

2. Assess receipt of quality-of-care metrics by baseline readmission risk

3. Characterize the association between quality-of-care metrics provided during TIA hospitalization and one-year risk of ischemic stroke readmission

Page 5: Presenter Disclosure Information

Hypotheses

• Patients with higher baseline ischemic stroke readmission risk are less likely to receive evidence-based care

• Receipt of evidence-based care is associated with lower rates of readmission for all baseline risk subgroups

Page 6: Presenter Disclosure Information

Methods• Data Sources

– Get With The Guidelines-Stroke Hospital-based quality improvement initiative Trained personnel abstract demographic, clinical, and event information at participating sites

– Probabilistic linkage to Medicare inpatient claims using indirect identifiers

• Study population– Starting population: N=108,527 TIA patients from 1326 GWTG sites– Exclusions:

Not linked to CMS data, or non-index records (N = 9145) Transferred out, hospice, death, or no documented discharge destination (N =3471) CMO (N = 435) Not enrolled in Medicare FFS at hospital discharge (N = 4721) Admitted after 2008 (N = 22,690) CMS discharge date after 2008 (N = 173)

– Final study population: N=58,809

Page 7: Presenter Disclosure Information

GWTG Readmission Risk Score

• Predicted probability of readmission based on patient baseline characteristics– Demographics– Comorbidities

• Cox proportional hazards modeling with backwards selection (stay criterion of p=0.05)

• Discriminative performance of the model examined using c-statistics and ROC curves

• Patients categorized into quintiles of predicted readmission risk

Page 8: Presenter Disclosure Information

Evidence-Based Care

• Individual– Antithrombotics by hospital day 2– Anticoagulation for patients with atrial fibrillation– Antithrombotics at discharge– Lipid-lowering medications at discharge– Smoking cessation counseling

• Global– TIA defect-free care: receipt of all measures for which the

patient was eligible

Page 9: Presenter Disclosure Information

Outcomes

– Primary Hospitalization for ischemic stroke

– Secondary All-cause mortality

Page 10: Presenter Disclosure Information

Statistical Analysis

• Baseline characteristics compared using Pearson Chi-squared and Wilcoxon rank sum tests

• Cox proportional hazards model to estimate risk for ischemic stroke readmission over one year in derivation cohort, with performance evaluation in validation cohort

• Censoring at death or loss of Medicare eligibility

• Cox models to estimate association between DFC and readmission within score quintiles

Page 11: Presenter Disclosure Information

Baseline Characteristics (%)

Variable

Stroke Readmission within 1 year

(N=3,318)

No Stroke Readmission within 1 year(N=54,854)

P-Value

Age, median 80.0 79.0 <.0001

Male gender 39.2 39.0 0.78

Black Race 10.3 7.4 <.0001

Prior stroke 44.6 34.4 <.0001

CAD/Prior MI 37.1 32.8 <.0001

Carotid stenosis 6.0 5.5 0.27

Diabetes 31.7 26.7 <.0001

PVD 6.6 5.2 .0004

Hypertension 81.8 81.2 0.40

Heart Failure 3.4 2.3 <.0001

Smoker 9.5 8.1 0.006

Dyslipidemia 39.3 45.1 <.0001

• One-year risk of ischemic stroke hospitalization=5.7%

Page 12: Presenter Disclosure Information

In-Hospital Quality Measures (%)

Variable

Stroke Readmission within 1 year

(N=3,318)

No Stroke Readmission within 1 year(N=54,854)

P-Value

Early Antithrombotics 96.8 96.3 0.28

Discharge Antithrombotics 95.9 95.7 0.71

Anticoagulants for AF 85.9 89.1 0.02

Statin (LDL>100 or ND) 59.4 61.4 0.04

Smoking Cessation 88.4 85.4 0.16

Defect-Free Care† 62.2 63.9 0.04

† Defect-free care=receipt of all TIA achievement measures for which the patient was eligible

Page 13: Presenter Disclosure Information

GWTG 1-Year IS Readmission Risk Score Model

Variable Hazard Ratio 95% CI

Age (per 10 year increase) 1.01 1.01, 1.02

White Race 0.79 0.72, 0.86

Atrial Fibrillation/Flutter 1.46 1.34, 1.58

Previous Stroke/TIA 1.45 1.35, 1.55

CAD/Prior MI 1.15 1.07, 1.23

Diabetes Mellitus 1.26 1.16, 1.36

Smoking 1.35 1.19, 1.52

Dyslipidemia 0.87 0.81, 0.93

Arrival Mode (EMS vs. Other) 1.20 1.12, 1.28

Ambulate Independently at Discharge 0.82 0.76, 0.88

C-statistic=0.603

Page 14: Presenter Disclosure Information

1-Year IS Readmission

0

5

10

15

20

25

1st 2nd 3rd 4th 5th

Ob

serv

ed R

isk

(%)

GWTG Readmission Risk Score Quintile

IS Readmission

Death

Overall 1-year Risk•Death: 11.8%•IS Readmission: 5.7%

*‡ GWTG Readmission for Stroke Risk Score estimated from age, gender, race, history of stroke/TIA, prosthetic heart valve, CAD/Prior MI, carotid stenosis, diabetes mellitus, PVD, hypertension, HF, smoker, dyslipidemia, hospital size, hospital type, and geographic region (c-statistic 0.59)

Page 15: Presenter Disclosure Information

Results

*‡ GWTG Readmission for Stroke Risk Score estimated from age, gender, race, history of stroke/TIA, prosthetic heart valve, CAD/Prior MI, carotid stenosis, diabetes mellitus, PVD, hypertension, HF, smoker, dyslipidemia, hospital size, hospital type, and geographic region (c-statistic 0.59)

50

60

70

80

90

100

1st 2nd 3rd 4th 5th

Early antithrombotics

Antithrombotics at discharge

Anticoagulation for AF

Statins

Smoking Cessation

DFC

%

GWTG Readmission Risk Score Quintile

Page 16: Presenter Disclosure Information

DFC and IS Readmission

0.7

1.4

1.0

Unadjusted 1st 2nd 3rd 4th 5th

GWTG Readmission Risk Quintile

HR

(95

% C

I)

Page 17: Presenter Disclosure Information

Limitations• Results may be influenced by residual confounding• Information about medication use after discharge not

available• Percent of TIA patients admitted at each GWTG

hospital not known• DFC is a composite measure and appears to be

driven largely by the statin use measure in this population

• Results may not be applicable to broader TIA patient population

Page 18: Presenter Disclosure Information

Conclusions• Patients who were readmitted for ischemic stroke within

one year of TIA had a greater comorbidity burden than patients who were not readmitted

• TIA patients with a high baseline risk of readmission for IS are less likely to receive defect-free care than low-risk patients, largely due to lack of statin treatment

• Standardized risk assessment and delivery of optimal inpatient care for TIA may help to reduce this apparent risk-treatment mismatch

Page 19: Presenter Disclosure Information

Acknowledgements

• The authors would like to thank the staff and participants of the GWTG-Stroke Registry for their important contributions to this work

Page 20: Presenter Disclosure Information

Thank you

Page 21: Presenter Disclosure Information

Candidate Risk Score VariablesAge (per 10 year increase)FemaleRace (White vs. Other)Medical History of Atrial Fibrillation/FlutterMedical History of Prosthetic Heart ValveMedical History of Previous Stroke/TIAMedical History of CAD/Prior MIMedical History of Carotid StenosisMedical History of Diabetes MellitusMedical History of PVDMedical History of HypertensionMedical History of SmokingMedical History of DyslipidemiaMedical History of HFAcademicRegion – NE vs. WRegion – MW vs. WRegion – S vs. W

Page 22: Presenter Disclosure Information

Risk Treatment Paradox • Documented for heart failure and acute MI (possibly

improving over time)• Uncertainty about the risk: benefit ratio in patients at

higher risk who are generally under-represented in randomized trials

• Information gaps in administrative datasets (i.e., lack of data on confounding clinical and functional variables that the clinician must weigh in making clinical decisions but which are not captured in administrative databases)

• Should also consider overutilization of nonevidence based therapies

Page 23: Presenter Disclosure Information

ABCD2 Score

-Validated for 2, 7, and 90 day IS but not long-term IS

Page 24: Presenter Disclosure Information

Readmission Risk Prediction

• Meta-analysis of 26 unique risk-prediction models• C-statistics: 0.55-0.65• Two of five found that addition of functional or

social variables improved discrimination• Limitations include lack of information on hospital

and systems-level factors, do not assess HRQOL, do not account for preventable readmissions

JAMA. 2011;306(15):1688-1698


Recommended